Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...

At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA ...

One study examines the small molecular cardiac myosin inhibitor for safety and efficacy at 96 weeks, and another compares it ...

The DeMenna family has helped shape Arizona law for generations as one of the Arizona Capitol’s most recognizable and respected public affairs firms.

Two experts discussed innovative trial designs in rare disease research, common challenges and the potential of AI to enhance ...

Placebo-subtracted mean weight loss up to 14.1%after 28 weeks with no plateauPotential for best-in-class tolerability with minimal diarrhea ...

Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...

A cannabis extract appears to provide sustained relief from chronic low back pain without signs of addiction or withdrawal, ...

By seeing yourself with grace, you create an internal safe space where you can grow. You can love your shadow and feel unconditional love, When you have your own back, you’ll feel braver to take the ...

Bayer announced today that data from across the KERENDIA ® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (HFSA)’s Annual Scientific ...

Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline ...

A state board unanimously voted Thursday to enact disciplinary sanctions on a Russellville physician after finding he had ...